A study published in the Journal of the National Comprehensive Cancer Network found that more than 80% of therapies tested in phase III oncology trials did not achieve meaningful clinical benefit in prolonging survival.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
